– USA, CA –  Zosano Pharma Corporation (NASDAQ: ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical executive, will become president and CEO of Zosano effective October 21, 2019. He will also serve on the company’s board of directors. Upon retiring after 48 years in the healthcare industry, John Walker will continue as the chairman of the company’s board of directors.

“We are extremely pleased that Steve will be taking over the leadership of the company,” said John Walker, chairman of Zosano. “His 25 years of experience in both large and small pharma organizations has given him the experience and perspective to lead the company through the continued development and, if approved by the FDA, the commercialization of Qtrypta and the further development of our intracutaneous delivery platform. From his early career at AstraZeneca through his 13 years of increasing responsibilities at Genentech and the successful launch of two biotech drugs at Corcept and Puma, he has demonstrated his leadership and ability to deliver results. As I transition back to my duties as chairman, I look forward to supporting him as he leads Zosano to success in the market.”

About Steve Lo

Steven Lo was most recently the chief commercial officer at Puma Biotechnology where he built the commercial operations infrastructure to launch the company’s first product, NERLYNX, in the United States and executed global licensing deals. Previously, he was senior vice president and chief commercial officer at Corcept Therapeutics. At Corcept, Mr. Lo formed the commercial organization to launch the company’s first product, Korlym, an endocrine specialty medication for a rare orphan disease and also was responsible for the corporate strategy and development of the company’s oncology franchise. Earlier in his career, he spent 13 years at Genentech in increasingly responsible roles in sales and marketing, ultimately serving as franchise head, Endocrinology. He started his career in the pharmaceutical industry at AstraZeneca.

Steven Lo added, “I am excited to join Zosano as we look to commercialize our first potential product, Qtrypta. I look forward to guiding the organization through the regulatory review process, commercial preparation and launch, as well as strategic partnering, where my experience will be most helpful. I’d like to thank John for his leadership in driving Zosano to this point and look forward to his continued counsel as chairman of the board.”

Mr. Lo holds a master’s in health administration from the University of Southern California and a B.S. in microbiology from the University of California, Davis.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of established molecules with established safety and efficacy profiles may provide an increased benefit to patients, for markets where patients remain underserved by existing therapies. The company’s Adhesive Dermally-Applied Microarray technology consists of titanium microneedles coated with drug that is designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is Qtrypta, which is an investigational, proprietary formulation of zolmitriptan delivered via ADAM technology, currently in development for the acute treatment of migraine. In February 2017, the company announced positive and statistically significant results from the ZOTRIP pivotal study and in February 2019, the company announced the completion of the final milestone in its long-term safety study. The company is preparing to submit a New Drug Application to the Food and Drug Administration for Qtrypta.

For more information: https://www.zosanopharma.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.